Search results for "MAb"

showing 10 items of 1716 documents

Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner

2017

Functional impairment of T-cells and a concomitant augmented expression of programmed death-1 (PD-1) have been observed in visceral leishmaniasis patients, as well as in experimental models for visceral and cutaneous leishmaniasis. The PD-1/PD-1-ligand (PD-1/PD-L) interaction negatively regulates T-cell effector functions, which are required for parasite control during leishmaniasis. The aim of this study was to elucidate the impact of the PD-1/PD-L axis in a human primary in vitro infection model of Leishmania major (Lm). Blocking the PD-1/PD-L interaction with nivolumab increased T-cell proliferation and release of the proinflammatory cytokines TNFα and IFNγ during the cocultivation of Lm…

lcsh:Immunologic diseases. Allergyprogrammed death-1 ligand 10301 basic medicineprogrammed death-1 ligand 2ImmunologyProinflammatory cytokine03 medical and health sciencesCutaneous leishmaniasisPD-L1medicineImmunology and AllergyLeishmania majorGranulysinOriginal Researchprogrammed death-1Leishmanianivolumabhuman macrophagesbiologyT-cellsmedicine.diseasebiology.organism_classification030104 developmental biologyGranzymePerforinImmunologybiology.proteinTumor necrosis factor alphahuman dendritic cellslcsh:RC581-607Frontiers in Immunology
researchProduct

Idarucizumab in High-risk Thoracic Surgery

2018

Direct oral anticoagulants have suggested a favorable profile compared with vitamin K antagonists. However, the lack of treatment to reverse the effect of direct oral anticoagulants has limited its use in some patients who require rapid reversal of anticoagulation, as those included in the transplant waiting list. Idarucizumab is a recently approved drug to reverse the anticoagulant effect of dabigatran. However, the clinical experience when using this drug is scarce. Herein, we present a clinical case on anticoagulation reversal with idarucizumab to perform heart and lung transplantation in a patient with Eisenmenger syndrome.

lcsh:RIdarucizumablcsh:MedicineAnticoagulantsCase ReportHeart-lung transplantation
researchProduct

Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply

2021

lcsh:RC705-779Pulmonary and Respiratory Medicine2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)SARS-CoV-2business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINECOVID-19lcsh:Diseases of the respiratory systemAntibodies Monoclonal HumanizedSeverity of Illness Indexchemistry.chemical_compoundTocilizumabchemistrySeverity of illnessHumansMedicinebusinessIntensive care medicineLetter to the Editor
researchProduct

Advanced characterization of a fully human IgG1 therapeutic monoclonal antibody by structure-activity relationship studies

2021

mAbs CharacterizationSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)
researchProduct

Reduced CD27−IgD− B Cells in Blood and Raised CD27−IgD− B Cells in Gut-Associated Lymphoid Tissue in Inflammatory Bowel Disease

2019

The intestinal mucosa in inflammatory bowel disease (IBD) contains increased frequencies of lymphocytes and a disproportionate increase in plasma cells secreting immunoglobulin (Ig)G relative to other isotypes compared to healthy controls. Despite consistent evidence of B lineage cells in the mucosa in IBD, little is known of B cell recruitment to the gut in IBD. Here we analyzed B cells in blood of patients with Crohn's disease (CD) and ulcerative colitis (UC) with a range of disease activities. We analyzed the frequencies of known B cell subsets in blood and observed a consistent reduction in the proportion of CD27−IgD− B cells expressing all Ig isotypes in the blood in IBD (independent o…

mass cytometrylcsh:Immunologic diseases. Allergyimmune system diseasesinflammatory bowel diseasememory B cellsGALThemic and immune systemschemical and pharmacologic phenomenabiologicslcsh:RC581-607digestive system diseasesustekinumabFrontiers in Immunology
researchProduct

A Novel Bio-Inspired Approach for High-Performance Management in Service-Oriented Networks

2021

Service-continuity in distributed computing can be enhanced by designing self-organized systems, with a non-fixed structure, able to modify their structure and organization, as well as adaptively react to internal and external environment changes. In this paper, an architecture exploiting a bio-inspired management approach, i.e., the functioning of cell metabolism, for specialized computing environments in Service-Oriented Networks (SONs) is proposed. Similar to the processes acting in metabolic networks, the nodes communicate to each other by means of stimulation or suppression chains giving rise to emergent behaviors to defend against foreign invaders, attacks, and malfunctioning. The mai…

maximum intensity projectionPerformance managementComputer sciencebio-inspired networksDistributed computingbio-inspired networks FPGA technology high-performance management Service-oriented networksbio-inspired networks; biomedical imaging; cerebral vascular tree reconstruction; FPGA technology; high-performance management; magnetic resonance angiography; maximum intensity projection; Service-oriented networksSoftwareGate arrayRobustness (computer science)Factor (programming language)Computer Science (miscellaneous)ArchitectureField-programmable gate arrayhigh-performance managementcomputer.programming_languagebusiness.industrymagnetic resonance angiographyComputer Science ApplicationsHuman-Computer InteractionTree (data structure)FPGA technologycerebral vascular tree reconstructionbiomedical imagingService-oriented networksbusinesscomputerInformation SystemsIEEE Transactions on Emerging Topics in Computing
researchProduct

Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer

2019

There is still a great unmet medical need concerning diagnosis and treatment of breast cancer which could be addressed by utilizing specific molecular targets. Tumor-associated MUC1 is expressed on over 90 % of all breast cancer entities and differs strongly from its physiological form on epithelial cells, therefore presenting a unique target for breast cancer diagnosis and antibody-mediated immune therapy. Utilizing an anti-tumor vaccine based on a synthetically prepared glycopeptide, we generated a monoclonal antibody (mAb) GGSK-1/30, selectively recognizing human tumor-associated MUC1. This antibody targets exclusively tumor-associated MUC1 in the absence of any binding to MUC1 on health…

medicine.drug_classEstrogen receptorMUC1Breast NeoplasmsMice TransgenicDeferoxamineMonoclonal antibody89Zr03 medical and health sciences0302 clinical medicineBreast cancerIn vivoCell Line TumorBiomarkers TumormedicineAnimalsHumansTissue Distributionskin and connective tissue diseasesMUC1Triple-negative breast cancermAbRadioisotopesMice Inbred BALB Cbiologybusiness.industryMucin-1breast cancer diagnosisAntibodies MonoclonalCancerGeneral MedicinePrognosismedicine.diseaseImmunohistochemistryMice Inbred C57BLPositron-Emission Tomographybiology.proteinCancer researchFemale030211 gastroenterology & hepatologyZirconiumAntibodybusinessResearch PaperInternational Journal of Medical Sciences
researchProduct

Overview of the second international workshop to define swine cluster of differentiation (CD) antigens

1998

The aim of the Second International Swine Cluster of Differentiation (CD) Workshop, supported by the Veterinary Immunology Committee (VIC) of the International Union of Immunological Societies (IUIS), was to standardize the assignment of monoclonal antibodies (mAb) reactive with porcine leukocyte differentiation antigens and to define new antibody clusters. At the summary meeting of the workshop in July, 1995, revisions in the existing nomenclature for the Swine CD were approved, so that the rules are now in accord with those for human and ruminant CD. Swine CD numbers will now be given to clusters of mAb to swine orthologues of human CD molecules when homology is proven by (1) suitable tis…

medicine.drug_classSwineCD3ImmunologyCluster of differentiation CDSwine; Cluster of differentiation (CD); Antigens; Monoclonal antibodies (mAb)Monoclonal antibodyEpitopeImmune systemAntigenMonoclonal antibodies (mAb)medicineAntigensInstituut voor Dierhouderij en DiergezondheidCluster of differentiation (CD)CD antigenGeneral VeterinaryCluster of differentiationbiologyID-LelystadVirologyID LelystadID-Lelystad Instituut voor Dierhouderij en DiergezondheidImmunologyID Lelystad Institute for Animal Science and Healthbiology.proteinAntibodyInstitute for Animal Science and Health
researchProduct

Novel Approaches for Immunosuppression in Graves’ Hyperthyroidism and Associated Orbitopathy

2020

<b><i>Background:</i></b> Both Graves’ hyperthyroidism (GH) and Graves’ orbitopathy (GO) are associated with significant adverse health consequences. All conventional treatment options have limitations regarding efficacy and safety. Most importantly, they do not specifically address the underlying immunological mechanisms. We aim to review the latest development of treatment approaches in these two closely related disorders. <b><i>Summary:</i></b> Immunotherapies of GH have recently demonstrated clinical efficacy in preliminary studies. They include ATX-GD-59, an antigen-specific immunotherapy which restores immune tolerance to the thyrotropin…

medicine.drug_classTeprotumumabbusiness.industryEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismImmunosuppressionImmunotherapyMonoclonal antibodyImmune toleranceThyrotropin receptor03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTocilizumabchemistry030220 oncology & carcinogenesisImmunologymedicineRituximabbusinessResearch Articlemedicine.drugEuropean Thyroid Journal
researchProduct

Comment on “Chronic spontaneous urticaria exacerbation in a patient with COVID‐19: rapid and excellent response to omalizumab”

2020

medicine.medical_specialty2019-20 coronavirus outbreakUrticariaCoronavirus disease 2019 (COVID-19)ExacerbationSARS-CoV-2business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Symptom Flare UpTreatment outcomeMEDLINECOVID-19OmalizumabDermatologyOmalizumabInternal medicineAnti-Allergic AgentsCorrespondenceHumansMedicineChronic Urticariabusinessmedicine.drugInternational Journal of Dermatology
researchProduct